Grants per year
- 1 - 25 out of 52 results
Search results
-
Finished
Prot #TL-895-203: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined with KRT-232 in Subjects with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
Altman, J. K. (PD/PI)
PSI Pharma Support America Inc., Telios Pharma, Inc.
5/4/21 → 5/4/24
Project: Research project
-
Prot #LOXO-IDH-20001: A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations
Altman, J. K. (PD/PI)
Medpace Clinical Research LLC, Loxo Oncology, Inc.
3/23/21 → 3/23/24
Project: Research project
-
Prot #KRT-232-104: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML)
Altman, J. K. (PD/PI)
INC Research, LLC, Kartos Therapeutics, Inc.
2/5/20 → 2/5/23
Project: Research project
-
Prot #A19-11184: Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
Altman, J. K. (PD/PI)
Theradex, Aprea Therapeutics AB
1/21/20 → 1/21/23
Project: Research project
-
Prot #CP-MGD006-01: A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Ri
Altman, J. K. (PD/PI)
7/5/19 → 7/5/22
Project: Research project
-
Prot #2215-CL-1101: Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)
Altman, J. K. (PD/PI)
Syneos Health, Inc., Astellas Pharma Global Development, Inc.
4/23/19 → 11/15/21
Project: Research project
-
Prot #BAY 1436032/19036: An open-label, non-randomized, multicenter Phase I study to determine the maximum tolerated and/or recommended Phase II dose of oral mutant IDH1 (mIDH1) inhibitor BAY 1436032 and to characterize its safety, tolerability, pharmacok
Altman, J. K. (PD/PI)
Covance Inc., Bayer HealthCare Pharmaceuticals, Inc.
2/22/18 → 6/1/19
Project: Research project
-
Prot #FF-10101-US101/201: A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
Quintiles, Inc., FUJIFILM Pharmaceuticals U.S.A., Inc.
8/2/17 → 8/2/23
Project: Research project
-
Prot #1315.2: An Open-Label, Phase I/II Trial To Determine The Maximum Tolerated Dose And Investigate Safety, Pharmacokinetics And Efficacy Of BI 836858 In Combination With Decitabine In Patients With Acute Myeloid Leukemia
Altman, J. K. (PD/PI)
Boehringer Ingelheim Pharmaceuticals, Inc.
2/13/17 → 2/13/20
Project: Research project
-
Prot #AG881-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients with Advanced Hematologic Malignancies with an IDH1 and/o
Altman, J. K. (PD/PI)
Novella Clinical, LLC, Agios Pharmaceuticals, Inc.
8/31/15 → 8/31/18
Project: Research project
-
MLN8237, an Aurora A kinase inhibitor, for treatment of myeloid malignancies
Crispino, J. D. (PD/PI), Altman, J. K. (Co-Investigator), Giles, F. J. (Co-Investigator), Stein, B. L. (Co-Investigator) & Wen, Q. (Other)
10/1/14 → 8/31/19
Project: Research project
-
Prot #AG120-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation
Altman, J. K. (PD/PI)
INC Research, LLC, Agios Pharmaceuticals, Inc.
7/31/14 → 7/31/22
Project: Research project
-
Prot #NU MSK12H10: A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients with Relapsed or Refractory Hairy Cell Leukemia
Altman, J. K. (PD/PI)
Genentech, Inc, Memorial Sloan Kettering Cancer Center
7/9/14 → 7/9/17
Project: Research project
-
Prot #CSLCT-AML-11-73: A Phase 1 Study of CSL362 (Anti-IL3Ra / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission with Incomplete Platelet Recovery at High Risk for Early Relapse
Altman, J. K. (PD/PI)
5/8/14 → 5/8/17
Project: Research project
-
Prot #AG221-C-001: A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects with Advanced Hematologic Malignancies with an IDH2 Mutation
Altman, J. K. (PD/PI)
INC Research, LLC, Agios Pharmaceuticals, Inc.
4/8/14 → 4/30/21
Project: Research project
-
Prot #CA180406: Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE
Altman, J. K. (PD/PI)
ICON Clinical Research, LLC, Bristol-Myers Squibb Company
3/10/14 → 3/10/17
Project: Research project
-
Prot #MEI-005: A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients with Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone
Altman, J. K. (PD/PI) & Dinner, S. N. (PD/PI)
SCRI Development Innovations, LLC, MEI Pharma, Inc.
3/7/14 → 3/7/17
Project: Research project
-
Improving Outcomes of Older and Medically Infirm Patients with AML
Adekola, K. (PD/PI) & Altman, J. K. (PD/PI)
Fred Hutchinson Cancer Research Center, Patient-Centered Outcomes Research Institute
1/1/14 → 6/30/18
Project: Research project
-
REDEFINE AYAO - Reducing Emotional Distress, Enhancing Function, and Improving Network Engagement in Adolescent and Young Adult Oncology
Victorson, D. E. (PD/PI), Altman, J. K. (Co-Investigator) & Sanford, S. D. (Co-Investigator)
American Cancer Society, Illinois Division, Inc.
12/1/13 → 11/30/16
Project: Research project